Stock comparison
BIOGEN INC. is 3.2x more valuable than ImmunityBio, Inc. by market capitalization ($29.37 B vs $9.29 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
BIIB is larger
BIOGEN INC. is 3.2x more valuable than ImmunityBio, Inc. by market capitalization ($29.37 B vs $9.29 B).
Market value leader
BIIB
BIOGEN INC. is 3.2x more valuable than ImmunityBio, Inc. by market capitalization ($29.37 B vs $9.29 B).
Revenue leader
BIIB
IBRX: $113.29M vs BIIB: $9.89B.
Profit leader
BIIB
IBRX: -$351.50M vs BIIB: $1.29B.
Margin leader
BIIB
IBRX: -310.3% vs BIIB: 13.1% net margin.
| Metric | IBRX | BIIB |
|---|---|---|
| Market cap | $9.29 B | $29.37 B |
| US-listed rank | #1001 | #476 |
| Revenue (latest FY) | $113.29M | $9.89B |
| Net income (latest FY) | -$351.50M | $1.29B |
| Net margin | -310.3% | 13.1% |
| P/E (trailing FY) | - | 22.7x |
| SEC filings | 528 | 2,690 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
BIOGEN INC. is 3.2x more valuable than ImmunityBio, Inc. by market capitalization ($29.37 B vs $9.29 B).
In their latest fiscal years, ImmunityBio, Inc. reported $113.29M in revenue while BIOGEN INC. reported $9.89B.
Full pages: ImmunityBio, Inc. and BIOGEN INC., or browse the full rankings.